Calvin Sandra 4

Accession 0001415889-25-003822

CIK 0001438533other

View on SEC.gov Company Profile

Filed

Feb 11, 7:00 PM ET

Accepted

Feb 12, 9:27 PM ET

Size

27.0 KB

Accession

0001415889-25-003822

Insider Transaction Report

Form 4

Period: 2025-02-11

Travere Therapeutics, Inc.TVTX

Calvin Sandra

SVP, CHIEF ACCOUNTING OFFICER

Transactions

Exercise/Conversion
Common Stock
2025-02-11$17.44/sh+10,000$174,400→ 73,654 total
Exercise/Conversion
Common Stock
2025-02-11$17.96/sh+10,000$179,600→ 73,654 total
Exercise/Conversion
Common Stock
2025-02-11$15.46/sh+15,000$231,900→ 78,654 total
Sale
Common Stock
2025-02-11$25.00/sh−9,244$231,100→ 54,410 total
Exercise/Conversion
Employee stock option (right to buy)
2025-02-11−10,000→ 0 total
Exercise: $16.23Exp: 2026-05-19→ Common Stock (10,000 underlying)
Exercise/Conversion
Employee stock option (right to buy)
2025-02-11−10,000→ 0 total
Exercise: $17.44Exp: 2027-05-17→ Common Stock (10,000 underlying)
Exercise/Conversion
Employee stock option (right to buy)
2025-02-11−10,000→ 0 total
Exercise: $17.96Exp: 2029-05-09→ Common Stock (10,000 underlying)
Exercise/Conversion
Employee stock option (right to buy)
2025-02-11−15,000→ 0 total
Exercise: $15.46Exp: 2030-01-31→ Common Stock (15,000 underlying)
Exercise/Conversion
Common Stock
2025-02-11$16.23/sh+10,000$162,300→ 73,654 total
Sale
Common Stock
2025-02-11$25.00/sh−10,000$250,000→ 63,654 total
Sale
Common Stock
2025-02-11$25.00/sh−10,000$250,000→ 63,654 total
Sale
Common Stock
2025-02-11$25.00/sh−10,000$250,000→ 63,654 total
Sale
Common Stock
2025-02-11$25.00/sh−15,000$375,000→ 63,654 total

Footnotes (6)

[F1]This sale was made pursuant to a written plan adopted on September 9, 2024, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option grant to the Reporting Person on May 19, 2016 with an expiration date of May 19, 2026.
[F2]This sale was made pursuant to a written plan adopted on September 9, 2024, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option grant to the Reporting Person on May 17, 2017 with an expiration date of May 17, 2027.
[F3]This sale was made pursuant to a written plan adopted on September 9, 2024, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option grant to the Reporting Person on May 9, 2019 with an expiration date of May 9, 2029.
[F4]This sale was made pursuant to a written plan adopted on September 9, 2024, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option grant to the Reporting Person on January 31, 2020 with an expiration date of January 31, 2030.
[F5]This sale was made pursuant to a written plan adopted on September 9, 2024, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.
[F6]The stock option is fully vested and exercisable.

Documents

1 file

4
form4-02132025_020258.xmlPrimary

Issuer

Travere Therapeutics, Inc.

CIK 0001438533

→

Entity typeother

Related Parties

filerCIK 0001882909

Filing Metadata

Form type: 4
Filed: Feb 11, 7:00 PM ET
Accepted: Feb 12, 9:27 PM ET
Size: 27.0 KB

View on SEC.gov